The future of diabetes medications: How CRISPR technology might play a role

Steven Moss*

DESCRIPTION

Diabetes is a global health crisis that affects over 537 million adults worldwide. It is a chronic condition characterized by high blood sugar levels, with two primary types: Type 1 and Type 2 diabetes. While current medications, such as insulin and oral drugs like metformin, help manage the disease, they do not cure it. As diabetes continues to rise in prevalence, researchers are exploring new ways to treat the condition, and one promising avenue is gene editing, particularly through CRISPR-Cas9 technology. This ground breaking tool could revolutionize diabetes treatment by addressing its root causes, rather than merely managing symptoms. Type 1 diabetes is an autoimmune disorder where the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This results in the need for lifelong insulin therapy to regulate blood sugar levels. In contrast, Type 2 diabetes is primarily caused by insulin resistance, where the body's cells fail to respond to insulin appropriately, often compounded by obesity, poor diet, and genetic factors. While oral medications like metformin and lifestyle changes can help manage Type 2 diabetes, they do not reverse the disease or restore normal insulin function. Both types of diabetes require ongoing management, but these current treatments fail to address the disease's underlying causes. This ability to make precise changes to the genome holds immense promise for treating genetic disorders, including diabetes. Type 1 diabetes occurs when the immune system destroys the beta cells in the pancreas, which are responsible for producing insulin. Current treatments, such as insulin injections or pumps, can help manage blood sugar levels but cannot replace the lost beta cells. CRISPR could offer a potential solution by editing the genes of immune cells to prevent them from attacking the pancreas. By reprogramming these immune cells, scientists hope to stop the autoimmune response that causes Type 1 diabetes. Another promising avenue is using CRISPR to generate new beta cells. In laboratory experiments, researchers have already used gene-editing techniques to manipulate stem cells into becoming insulin-producing beta cells. These cells could then be transplanted into patients, providing a source of insulin production. CRISPR might even be able to regenerate functional beta cells within the patient's own pancreas, offering a more sustainable and natural form of treatment. By correcting these genetic factors, CRISPR could help restore the body's natural insulin sensitivity, offering a more effective treatment than current medications. Moreover, CRISPR could also be used to enhance beta cell function or even generate new beta cells in the pancreas, improving insulin production and secretion in people with Type 2 diabetes. While CRISPR holds great promise for revolutionizing diabetes treatment, its use raises ethical and safety concerns. One of the primary challenges is the risk of off-target effects, where the CRISPR system might unintentionally alter other parts of the genome, potentially causing harmful mutations. As a result, much of the current research is focused on improving the precision and reliability of the technology. Ethical concerns also arise when considering the potential use of CRISPR for germline editing altering the genetic code in embryos or reproductive cells. The ability to edit the genetic makeup of future generations raises questions about consent, equity, and unintended consequences. Therefore, any clinical use of CRISPR in humans must be carefully regulated and subject to ethical review.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The author has nothing to disclose and also state no conflict of interest in the submission of this manuscript.

Department of Medicine, University of Sydney, Australia

Corresponding author: *Steven Moss*

E-mail: *mosssteve@gmail.com*

Received: *01 October 2024, Manuscript No. ajdm-24-150384;* ***Editor assigned:*** *03 October 2024, PreQC No ajdm-24-150384 (PQ);* ***Reviewed:*** *17 October 2024, QC No ajdm-24-150384;* ***Revised:*** *22 October 2024, Manuscript No. ajdm-24-150384 (R);* ***Published:*** *29 October 2024,* ***DOI:*** *10.54931/AJDM-32.5.8.*